featured
Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer (innovaTV 204/GOG-3023/ENGOT-cx6): A Multicentre, Open-Label, Single-Arm, Phase 2 Study
Lancet Oncol 2021 Apr 09;[EPub Ahead of Print], RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, D Cibula, B Lund, L Woelber, S Pignata, F Forget, A Redondo, SD Vindeløv, M Chen, JR Harris, M Smith, LV Nicacio, MSL Teng, A Laenen, R Rangwala, L Manso, M Mirza, BJ Monk, I VergoteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.